spacer
home > > summer 2002 > are you ready for edc technology transfer?
PUBLICATIONS


Are You Ready for EDC Technology Transfer?

The use of electronic data capture (EDC) for clinical trials as an internal application by the pharmaceutical industry is continuing to gain momentum. To date, most EDC clinical trials are utilising EDC software on an application service provider (ASP) basis, meaning that the sponsor licenses the software on a trial-by-trial basis, relying on the vendor for the support functions of training, trial development, hosting and help desk, among others. Now that clinical organisations have become familiar with various EDC applications through outsourced projects, many are planning to bring this technology in-house. However, as with any software implementation project, significant planning and readiness is essential for success. At any given time there are tens of thousands of software projects taking place around the world. Up to two-thirds of projects will exceed schedule and/or budget, and of the most expensive projects, nearly half will be cancelled because they are viewed as being 'out of control'.

Successful software projects demand careful planning and deliberate execution. Conversely, software projects are more likely to fail for two reasons - lack of knowledge and/or lack of resolve to conduct software projects successfully. By fully educating yourself about what needs to take place during this transition and by carefully planning the execution, you can greatly improve your odds of success.

What

What do you hope to accomplish with EDC in-house? This question alone might give pause for thought. As a clinical trial sponsor, you most likely have EDC in the field at investigator sites and with monitors, but are you ready to design and build e-CRFs yourself? Are you able to provide hosting services for the central repository where all of the clinical data will ultimately be collected? Can you provide help desk services to address functional and/or technical questions from investigators and monitors at remote locations? Considering these questions can help you decide if you should take a phased approach to EDC implementations or bring it in-house all at once.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Brian Dakin, Director of the Project Management Office at CB Technologies, Inc.

Brian Dakin is the Director of Project Management at CB Technologies, Inc. He joined the organisation in 1998 and is responsible for the management of ASP trials as well as technology transfer engagements. Brian co-ordinates activities across many of the departments that provide the services necessary to support MetaTrialTM EDC-based clinical trials.

Prior to joining CB, Brian held positions in management consulting at Coopers & Lybrand and Ernst & Young, with a focus on systems implementation and process improvement. He has a BS in Industrial Engineering and an MBA from Lehigh University.

spacer
Brian Dakin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High throughput, low energy consumption: AVENTUS to showcase high-performance packaging systems at interpack

• Joint venture for a broad range of solutions • Powerful and low-maintenance units for free-flowing bulk materials • Solutions for agriculture as well as the chemicals, salts, fertilisers pet food and animal feed industries
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement